Acquired chemotherapy resistance in ovarian cancer.

about

MuvB: A Key to Cell Cycle Control in Ovarian Cancer.Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase

P2860

Q55286778-6201BB69-1E26-4827-94B9-7862C24975FE Q59126829-28CF26A9-507C-4335-BE74-5692F1078714

P2860

Acquired chemotherapy resistance in ovarian cancer.

Item

http://www.wikidata.org/entity/Q49896015

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Acquired chemotherapy resistance in ovarian cancer.

@en

Acquired chemotherapy resistance in ovarian cancer.

@nl

type

Item

label

Acquired chemotherapy resistance in ovarian cancer.

@en

Acquired chemotherapy resistance in ovarian cancer.

@nl

prefLabel

Acquired chemotherapy resistance in ovarian cancer.

@en

Acquired chemotherapy resistance in ovarian cancer.

@nl

P1476

Acquired chemotherapy resistance in ovarian cancer

@en

P2093

D D L Bowtell

http://www.w3.org/2001/XMLSchema#string

E L Christie

http://www.w3.org/2001/XMLSchema#string

P2860

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.

Integrated genomic analyses of ovarian carcinoma

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.

DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.

Rethinking ovarian cancer: recommendations for improving outcomes.

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.

P304

viii13-viii15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1093/ANNONC/MDX446

http://www.w3.org/2001/XMLSchema#string

P433

suppl_8

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David Bowtell

Elizabeth L Christie

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29232469

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

chemotherapy

Acquired chemotherapy resistance in ovarian cancer.

about

P2860

P2860

Acquired chemotherapy resistance in ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921